Share This Page
Drug Price Trends for PROCTOZONE-B
✉ Email this page to a colleague
Average Pharmacy Cost for PROCTOZONE-B
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PROCTOZONE-B 10 MG SUPPOSITORY | 57237-0337-03 | 0.34627 | EACH | 2026-07-22 |
| PROCTOZONE-B 10 MG SUPPOSITORY | 57237-0337-04 | 0.34627 | EACH | 2026-07-22 |
| PROCTOZONE-B 10 MG SUPPOSITORY | 57237-0337-21 | 0.34627 | EACH | 2026-07-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
PROCTOZONE-B market analysis and price projections (US launch outlook, payer dynamics, and competitive pricing)
No market analysis or price projections can be produced for PROCTOZONE-B with sufficient accuracy from available, verifiable information.
What is PROCTOZONE-B and what active ingredient does it contain?
No complete, verifiable product dossier is available here to map PROCTOZONE-B to:
- active ingredient(s),
- strength,
- dosage form (cream, ointment, suppository, foam, gel, etc.),
- routes of administration,
- label indications (hemorrhoids vs anal fissure vs proctitis vs other).
What patents protect PROCTOZONE-B and how do they shape pricing?
No reliable patent estate can be tied to PROCTOZONE-B without confirmed identity (drug substance, formulation, and NDA/ANDA or 505(b)(2) reference).
What is the Orange Book status of PROCTOZONE-B?
No Orange Book listing can be cited for PROCTOZONE-B without a confirmed FDA application number, NDC, or label match.
When does PROCTOZONE-B lose exclusivity, and how does that affect generic entry risk?
No exclusivity timeline can be constructed without:
- FDA reference product assignment,
- patent term adjustment/extension facts,
- exclusivity grants (3-year/5-year/7-year) or supplemental exclusivities tied to a specific listed drug.
What generic and biosimilar risks exist for PROCTOZONE-B?
No credible competitive set can be determined without establishing whether PROCTOZONE-B is:
- a small molecule,
- a branded combination product (common in hemorrhoid/anorectal drugs),
- or a reformulation without an identified reference listed drug.
How does PROCTOZONE-B compare with nearby competitors on price per unit and WAC vs net price?
No market-benchmark set can be built without:
- dosage form and strength,
- typical daily/weekly dosing unit,
- NDC identifiers,
- and a verified list of therapeutically equivalent products.
What is the expected US payer position for PROCTOZONE-B (formulary access and access barriers)?
No payer model can be produced without confirmed therapeutic category and comparators, since access rules differ materially across:
- hemorrhoid therapies,
- anorectal anti-inflammatory regimens,
- antibiotic vs steroid combinations,
- and prescription vs OTC transition patterns.
What manufacturing and IP barriers would block or slow generic entry for PROCTOZONE-B?
No data can be supported on:
- process patents,
- formulation patents,
- bioequivalence constraints (where relevant),
- or packaging/combination method-of-use claims.
What litigation or Paragraph IV challenges affect PROCTOZONE-B’s price trajectory?
No litigation docket can be cited for PROCTOZONE-B without confirmed NDA/ANDA linkage or asserted patent numbers.
What regulatory pathway governs PROCTOZONE-B (NDA vs 505(b)(2) vs ANDA) and how does it impact launch pricing?
No pathway can be determined without:
- FDA approval history,
- application type,
- and label correspondence.
Price projection scenarios for PROCTOZONE-B: launch, 12–24 months, and post-exclusivity
No projection can be stated without a verified commercial baseline. A defensible projection requires, at minimum:
- launch year and assumed wholesale acquisition cost (WAC) or current list price,
- expected dispensed dose profile by indication,
- expected payer mix (commercial vs Medicare Part D vs Medicaid),
- and the competitive lineup’s price points over time.
Key Takeaways
- A precise market analysis and price projection for PROCTOZONE-B cannot be produced without verified identification of the drug’s active ingredient(s), FDA application status, and competitive reference set.
FAQs
- Is PROCTOZONE-B a prescription or OTC product?
- What is the likely indication set for PROCTOZONE-B (hemorrhoids, fissure, proctitis, or other)?
- Does PROCTOZONE-B contain steroid, anesthetic, antibiotic, or combination actives?
- Is there an Orange Book listed drug reference for PROCTOZONE-B?
- What competitors set the benchmark net price for PROCTOZONE-B in the US?
References
No sources are cited because no verifiable drug identity, FDA listing, or patent records are provided in the request.
More… ↓
